Sun Pharma reports strong growth, specialty sales surge
Sun Pharma (BSE: SUNPHARMA) reported strong financial results, with FY24 sales reaching Rs 477.58 Bn, a 10% increase year-over-year. Adjusted net profit rose 16% to Rs 100.71 Bn. The company's specialty business is a key growth driver, accounting for 32% of US revenue. With increased focus on research and development, Sun Pharma invested Rs 31.78 Bn in FY24. The company aims to sustain topline growth by enhancing the specialty product portfolio, expanding in emerging markets, and optimizing operational efficiency. A strong global presence, with operations in over 100 countries, allows the company to make strategic acquisitions, which are critical for sustaining growth and strengthening its position in key therapeutic areas.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Sun Pharmaceutical Industries publishes news
Free account required • Unsubscribe anytime